FDA denies MDMA PTSD treatment approval due to abuse and long-term concerns, sparking debate.

The FDA denied approval for MDMA as a PTSD treatment, sparking debate among patients, researchers, and advocates. Clinical trials showed promising results, but concerns over potential abuse and long-term effects led to refusal. Supporters argue MDMA-assisted therapy outweighs risks, while critics stress on safer alternatives. The decision raises questions about the FDA's approval process and the future of unconventional treatments.